Pattern of disease and response to pembrolizumab in recurrent cervical cancer

OBJECTIVE: Since the approval of pembrolizumab for advanced or recurrent PD-L1 positive (CPS > 1%) cervical cancer, the clinical characteristics associated with response have remained undefined. We sought to characterize the clinicopathologic features of patients with advanced cervical cancer at...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol Rep
Main Authors: Miller, Kathryn M., Filippova, Olga T., Hayes, Sara A., Abu-Rustum, Nadeem R., Aghajanian, Carol, Broach, Vance, Ellenson, Lora H., Selenica, Pier, Jewell, Elizabeth L., Kyi, Chrisann, Lakhman, Yuliya, Mueller, Jennifer J., O'Cearbhaill, Roisin E., Park, Kay J., Sonoda, Yukio, Zamarin, Dmitriy, Weigelt, Britta, Leitao, Mario M., Friedman, Claire F.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Research Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8319446/
https://ncbi.nlm.nih.gov/pubmed/34345644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2021.100831
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados